A Fundação Grünenthal utiliza cookies próprios e de terceiros para melhorar a experiência de navegação, oferecer conteúdo personalizado e melhorar os seus serviços. Utilizamos scripts analíticos que colocam um cookie de rastreamento mas apenas ativamos esses serviços com o seu consentimento. Se clicar em “Aceitar”, está a consentir com a utilização desses scripts analíticos.

Pode retirar o seu consentimento em qualquer altura Para o fazer, modifique as suas configurações neste Website seguindo este link para a nossa Declaração de Privacidade com as opções de configuração: Ir a definições

Aceitar

;

10/11/2019

Lisboa, 11 de outubro de 2019 – A Fundação Grünenthal acaba de atribuir o Prémio Grünenthal Dor 2018, no valor total de 15 mil euros, a duas equipas de investigadores na área da dor, com trabalhos de investigação clínica e investigação básica.

Mesoblast will receive up to US$150 million in upfront and milestone payments prior to product launch, as well as further commercialisation milestone payments. These payments include commitments up to US$45 million within the first year comprising US$15 million on signing, US$20 million on receiving regulatory approval to begin a confirmatory Phase III trial in Europe, and US$10 million on certain clinical and manufacturing outcomes. Cumulative milestone payments could exceed US$1 billion depending on the final outcome of Phase III studies and patient adoption. Mesoblast will also receive tiered double digit royalties on product sales. Mesoblast is completing a Phase III trial for MPC-06-ID in the U.S. which will read out in 2020. In a previous U.S. Phase II trial, Mesoblast demonstrated that a single intra-discal injection of MPC-06-ID using a unit dose of 6 million allogeneic mesenchymal precursor cells (MPCs) resulted in meaningful and durable improvements for patients in pain intensity and functionality for at least three years1. 

Grünenthal and Mesoblast have agreed on an overall development plan for MPC-06-ID to meet European regulatory requirements. As part of this plan, the companies will collaborate on the study design for a confirmatory Phase III trial in Europe. The results of the two Phase III trials are expected to support both U.S. FDA and European EMA regulatory approvals for MPC-06-ID in chronic low back pain due to degenerative disc disease.

Grünenthal’s CEO Gabriel Baertschi said: “This is an exciting day for Grünenthal. Cell-based therapies offer a novel approach in pain management. They can potentially deliver meaningful lasting improvements to patients beyond symptomatic treatment by maintaining or even restoring physiological function. By teaming up with Mesoblast for the next generation of pain therapies for chronic low back pain due to degenerative disc disease, we are diligently executing our strategy: leveraging promising new therapeutic modalities and addressing patients with high unmet medical needs. This is an important next step in working towards our vision of a world free of pain.”

Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very pleased to enter into this strategic partnership with Grünenthal, a world leader in innovative approaches to pain management. Together with Grünenthal we plan to bring an important new class of therapy for pain management to the many patients suffering with degenerative disc disease. This partnership is in line with our corporate strategy to team up with best in category commercial leaders to maximise market access for our innovative cellular medicines for the treatment of patients suffering from debilitating or life-threatening inflammatory conditions.”

MPCs have generated great interest in clinical science and medicine due to their immunomodulatory effects and their role in tissue repair and regeneration. These cells have been shown to be effective in reducing inflammation and promoting the regeneration of host tissues through cell-to-cell interactions and secretion of a wide range of endogenous analgesic and anti-inflammatory molecules2,3. Furthermore, in degenerative disc disease, these cells could contribute to regenerating physiological disc tissue by promoting the proliferation of host chondrocytes and their secretion of tissue matrix components4. Among key characteristics of MPCs are their capacity for significant expansion in culture and their relative lack of immunogenicity. These properties facilitate their use as allogeneic, or “off-the-shelf”, therapeutics with well-defined release criteria and batch-to-batch reproducibility that meet stringent regulatory requirements.  

Sobre a Fundação Grünenthal:

A Fundação Grünenthal é uma entidade sem fins lucrativos que tem por fim primordial a investigação e a cultura científica na área das ciências médicas, com particular dedicação ao estudo da dor e respetivo tratamento.

Para mais informações consulte www.fundacaogrunenthal.pt

Maria João Serra

ATREVIA Lisboa


E-Mail mmoreira@atrevia.com

Phone 21 324 02 2

Mobile 914 027 327


Carina Monteiro

ATREVIA Lisboa


E-Mail cmonteiro@atrevia.com

Phone 21 324 02 2

Mobile 914 027 327